Kuan-Ling Lin1, Kuo-Sheng Lee2, Cheng-Chien Yang3, Li-Chun Hsieh3, Chin-Hui Su3, Fang-Ju Sun4. 1. Department of Otolaryngology-Head and Neck Surgery, Mackay Memorial Hospital, Hsinchu, Taiwan. 2. Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. kslee147@ms31.hinet.net. 3. Department of Otolaryngology-Head and Neck Surgery, Mackay Memorial Hospital, Taipei, Taiwan; Department of Audiology and Speech language pathology , Department of Medicine , Mackay Medical College, Taipei, Taiwan; Department of Medicine , Taipei Medical University, Taipei, Taiwan. 4. Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan.
Abstract
OBJECTIVES/HYPOTHESIS: Patients with congenital nasal pyriform aperture stenosis (CNPAS) may become less symptomatic with age. Therefore, we aimed to develop a growth curve of the pyriform aperture so that a more comprehensive plan can be designed for CNPAS patients who show little response to conservative treatment. STUDY DESIGN: A single-institution study, retrospective review of CNPAS patients during the period November 1997 to December 2014. METHODS: We measured the distances between the bilateral nasal processes of the maxilla (interprocess distance [IPD]) on three-dimensional computed tomography images and then divided the patients into five different age groups. A growth curve of the pyriform aperture was then constructed based on the distance-age relationship. RESULTS: Fifty-four IPD measurements were included. The mean IPD was 3.57 mm in neonates < 1 month old, 4.08 mm in infants aged 1 to 3 months, 5.19 mm in the 4-month to 11-month age group, 6.61 mm in the 12-month to 36-month age group, and 9.20 mm in children > 36 months of age. We found that the cubic curve was the most appropriate growth curve, and that growth tended to be slower from 3.5 years to 6 years of age. CONCLUSIONS: The growth curve of the pyriform aperture in children with CNPAS developed in this study can aid in treatment planning and predict clinical outcome of CNPAS patients. Although CNPAS patients may become less symptomatic with age, when the observed IPD falls progressively farther from the curve, more aggressive intervention should be considered, such as changing the management strategy from observation to conservative treatment or from conservative treatment to surgery. LEVEL OF EVIDENCE: 4 Laryngoscope, 126:2399-2402, 2016.
OBJECTIVES/HYPOTHESIS: Patients with congenital nasal pyriform aperture stenosis (CNPAS) may become less symptomatic with age. Therefore, we aimed to develop a growth curve of the pyriform aperture so that a more comprehensive plan can be designed for CNPAS patients who show little response to conservative treatment. STUDY DESIGN: A single-institution study, retrospective review of CNPAS patients during the period November 1997 to December 2014. METHODS: We measured the distances between the bilateral nasal processes of the maxilla (interprocess distance [IPD]) on three-dimensional computed tomography images and then divided the patients into five different age groups. A growth curve of the pyriform aperture was then constructed based on the distance-age relationship. RESULTS: Fifty-four IPD measurements were included. The mean IPD was 3.57 mm in neonates < 1 month old, 4.08 mm in infants aged 1 to 3 months, 5.19 mm in the 4-month to 11-month age group, 6.61 mm in the 12-month to 36-month age group, and 9.20 mm in children > 36 months of age. We found that the cubic curve was the most appropriate growth curve, and that growth tended to be slower from 3.5 years to 6 years of age. CONCLUSIONS: The growth curve of the pyriform aperture in children with CNPAS developed in this study can aid in treatment planning and predict clinical outcome of CNPAS patients. Although CNPAS patients may become less symptomatic with age, when the observed IPD falls progressively farther from the curve, more aggressive intervention should be considered, such as changing the management strategy from observation to conservative treatment or from conservative treatment to surgery. LEVEL OF EVIDENCE: 4 Laryngoscope, 126:2399-2402, 2016.
Authors: L Ríos; T L Kivell; C Lalueza-Fox; A Estalrrich; A García-Tabernero; R Huguet; Y Quintino; M de la Rasilla; A Rosas Journal: Sci Rep Date: 2019-02-08 Impact factor: 4.379